ArticleMolecular nutrition & food research2025
Obesity Parameters in Women Is Associated With AMY1 Gene Copy Number, Nesfatin-1 Level, and Dietary Intake: A Case-Control Study.
Article in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of salivary amylase gene copy number on metabolic health.Frontiers in nutrition · 2026Review
- Obesity Parameters in Women Is Associated With AMY1 Gene Copy Number, Nesfatin-1 Level, and Dietary Intake: A Case-Control Study.Molecular nutrition & food research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AMY1 gene copy number (GCN) variations and the satiety hormone Nesfatin-1 have recently emerged as potential contributors to obesity and related metabolic disturbances. This study evaluated the relationship between AMY1 GCN, Nesfatin-1 level, and nutritional status in obese/overweight and normal-weight women. Participants included 40 normal-weight and 45 overweight/obese women aged 19-50. Data were collected through a demographic and dietary habits questionnaire, a 3-day food recall, anthropometric measurements, and body composition analysis via bioelectrical impedance. Saliva samples were used to measure AMY1 GCN and Nesfatin-1 levels. The AMY1 GCN was significantly lower in overweight/obese participants compared to normal-weight participants. Increased AMY1 GCN was associated with a decrease in BMI (-0.154 units), while increased Nesfatin-1 level was linked to a rise in BMI (0.196 units) (p < 0.05). Women with low AMY1 GCN had higher daily intakes of energy, carbohydrate, protein, and fat (p < 0.05). This study highlights the significant roles of AMY1 GCN and Nesfatin-1 in the development of obesity. The findings suggest that lower AMY1 GCN and higher Nesfatin-1 levels are associated with unfavorable nutritional and metabolic profiles. Further comprehensive studies on genetic and hormonal factors, including AMY1 GCN and Nesfatin-1, are recommended to guide obesity prevention and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.